Patent ID: 8846613

Claim:
A pharmaceutical composition comprising a compound having the following structure and/or a compound having the following structure or a pharmaceutically acceptable salt thereof in combination with at least one second therapeutic agent 2 which is suitable in the treatment of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance (IGT), impaired fasting blood glucose (IFG), atherosclerose, glaucoma and hyperglycemia; wherein the at least one second therapeutic agent (2) is selected from the group consisting of: 2.a) biguanides, 2.b) sulfonylureas, 2.c) meglitinides, 2.d) thiazolidindiones, 2.e) alpha-glucosidase inhibitors, 2.f) insulins and insulin analogues, 2.g) dipeptidyl peptidase IV inhibitors (DPP IV inhibitors) 2.h) SGLT 2 inhibitors, 2.i) PPAR gamma/alpha modulators, 2.j) glucose-dependent insulinotropic polypeptide agonists, 2.k) beta-3 agonists, 2.l) GLP1 and GLP1 analogues, 2.m) PPAR gamma modulators, 2.n) HMG-CoA reductase inhibitors, and 2.o) PPAR delta modulators.